Description: Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Home Page: www.kintor.com.cn
No. 20 Songbei Road
Suzhou,
215123
China
Phone:
86 51 2626 39909
Officers
| Name | Title |
|---|---|
| Dr. Youzhi Tong | Founder, CEO & Exec. Chairman |
| Ms. Yan Lu | CFO, Joint Company Sec. & Exec. Director |
| Dr. Qun Lu | Chief Technology Officer |
| Mr. Ma Liandong | VP and Head of R&D Institute |
| Mr. Wai Chiu Wong FCS | Joint Company Sec. |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 12.6904 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.2233 |
| Price-to-Sales TTM: | 135.9484 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 328 |